A Study to Evaluate the Efficacy and Safety of Dupilumab in Adult Patients With Bullous Pemphigoid
Completed · Phase 2/Phase 3 · Has a placebo group
Conditions studied: Bullous Pemphigoid
In brief
The main purpose of this study is to investigate whether dupilumab is effective and safe for the treatment of bullous pemphigoid. Dupilumab is a type of drug called a "monoclonal antibody". An antibody is a special kind of protein that the immune (defense) system normally makes to fight bacteria and viruses. Bullous pemphigoid is an autoimmune subepidermal blistering disease, predominately affecting the elderly (typical onset after age 60). The study is looking at several other research questions, including: * Side effects that may be experienced by people taking dupilumab * How dupilumab works in the body and affects the body * How dupilumab affects quality of life * How much dupilumab is present in the blood * To see if dupilumab works to wean the patient off oral corticosteroids
Key facts
- Study ID
- NCT04206553
- Run by
- Regeneron Pharmaceuticals
- People needed
- 106
- Starts
- 2020-10-28
- Expected to finish
- 2025-01-05
- Last updated by the study team
- 2026-06-18
Who can join
Age: 18 and older, up to 90. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Regeneron Study Site — Scottsdale, Arizona, United States
- Regeneron Study Site — Redwood City, California, United States
- Regeneron Study Site — Farmington, Connecticut, United States
- Regeneron Study Site — Miami, Florida, United States
- Regeneron study Site — Orlando, Florida, United States
- Regeneron Study Site — Iowa City, Iowa, United States
- Regeneron Study Site — Boston, Massachusetts, United States
- Regeneron study Site — Ann Arbor, Michigan, United States
- Regeneron Study Site — Chapel Hill, North Carolina, United States
- Regeneron Study Site — Portland, Oregon, United States
- Regeneron Study Site — Philadelphia, Pennsylvania, United States
- Regeneron study Site — Providence, Rhode Island, United States
- Regeneron Study Site — Murray, Utah, United States
- Regeneron study Site — Charlottesville, Virginia, United States
- Regeneron Study Site — Kogarah, New South Wales, Australia
- Regeneron Study Site — Box Hill, Victoria, Australia
- Regeneron Study Site — Bobigny, France
- Regeneron Study Site — Bordeaux, France
- Regeneron Study Site — Lille, France
- Regeneron Study Site — Nice, France
- Regeneron Study Site — Paris, France
- Regeneron Study Site — Rouen, France
- Regeneron Study Site — Münster, North Rhine-Westphal, Germany
- Regeneron Study Site — Mainz, Rhineland-Palatinate, Germany
- Regeneron study Site — Birmingham, Alabama, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.